Melbourne, Australia; 25 May 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that Starpharma’s DEP™ cabazitaxel eliminated neutropenia typical of cabazitaxel (Jevtana^®) in a preclinical study. 

The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio. 

Go to the article (external link)

Starpharma is presenting today at The CEO Session Series event in Sydney.

Starpharma and Ansell today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect™ VivaGel^® condoms for the upcoming Olympic Games in Rio de Janeiro.

Starpharma announced today that the VivaGel^® active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel^® condom.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2016.

In this issue:

> Message from the CEO

> Adama licenses Priostar^® for 2,4-D

> DEP^TM cabazitaxel shows superior performance

> Starpharma's Targeted DEP^TM conjugates - compelling results in an area of high interest

> AstraZeneca selects second DEP^TM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel^® BV in Australia and New Zealand

> MOU for VivaGel^® condom in China

> Half-year financial results

> Bio-Europe^® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

Starpharma today announced that it will present this week at the Bio-Europe^® conference in Stockholm. At the conference Starpharma will also be conducting partnering discussions with pharmaceutical companies for VivaGel^® BV, DEP^TM and other parts of Starpharma’s portfolio.

Starpharma today announced further efficacy results of its most recent DEP™ candidate, DEP™ cabazitaxel, in a human breast cancer model. These data will be presented along with an overview of Starpharma’s DEP™ platform at the BioEurope Spring 2016 conference in Stockholm later this week.

Starpharma and Adama today announced the licensing by Adama of Starpharma's Priostar^® dendrimer technology for the development and commercialization of an enhanced, proprietary 2,4-D herbicide for the US market. 2,4-D is one of the top three herbicides sold world-wide, with global sales in 2014 estimated by Phillips McDougall to be around US$680 million. The US market in 2014 was worth approximately US$115 million, and has been projected by the US Department of Agriculture to grow by more than 70% by 2020.